Infections
233 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| "Synchronised" arm (intervention) for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 4,4',4''-(4-PROPYL-(1H)-PYRAZOLE-1,3,5-TRIYL)TRISPHENOL for leptospirosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 4CMenB vaccine for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| 9vHPV Vaccine for papillomavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo + Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acoziborole for trypanosomiasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acoziborole for trypanosomiasis, african | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amoxicillin for treponemal infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ansuvimab for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artemether + Lumefantrine for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artemether + Lumefantrine + TAFENOQUINE for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| artemether-lumefantrine for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| artemether-lumefantrine + Mosquirixs for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artesunate for cytomegalovirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atovaquone-Proguanil for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atovaquone-Proguanil for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake timed prone and repositioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7760 for sepsis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7760 for staphylococcal infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bacillus calmette-guerin live antigen, unspecified substrain for tuberculosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bedaquiline for tuberculosis, multidrug-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benznidazole for chagas disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezlotoxumab for clostridium infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blmz for tuberculosis, multidrug-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood and adrenaline for cholera | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood and adrenaline for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BPaLMZ Regimen for latent tuberculosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabamiquine for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chlorhexidine for infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| coadministration for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Coartem® Baby for malaria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for haemophilus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®: DTaP for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®: DTaP for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin + Piperaquine tetraphosphate for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin + Piperaquine tetraphosphate + TAFENOQUINE for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin-Piperaquine (DP) for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for diphtheria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for tetanus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dolutegravir + Isoniazid + RIFAPENTINE for latent tuberculosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV and ActHIB® for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV and ActHIB® for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV combined vaccine for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTaP-IPV combined vaccine for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efineptakin alfa for opportunistic infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EG-MCV4 for meningococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ervebo® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etofenprox-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Factory-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal bacteriotherapy (FBT) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbial Transplantation for clostridium infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Fecal Microbiota Transplant for clostridium infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Fecal Microbiota Transplant (FMT) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota transplant (Promicrobioma) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation (FMT) for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation (FMT) + ISOTONIC SODIUM CHLORIDE SOLUTION for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal microbiota transplantion (FMT) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Transplant for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Virome Transplantation for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fidaxomicin for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flucytosine (5FC) for mycoses | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flucytosine (5FC) + Liposomal Amphotericin B (LAmB) for mycoses | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluvoxamine for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fmt for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| FMT (Fecal Microbiota Transplantation) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FMT-c Lactobacillus for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation B for pneumococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation C for pneumococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation D for pneumococcal infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fosravuconazole + benznidazole for chagas disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fresh FMT for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Frozen-and-Thawed FMT for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gepotidacin for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| GSK malaria vaccine 257049 Vaccine for malaria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Healthy donor stool for clostridium infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hemoperfusion for leptospirosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hydroxychloroquine + azithromycin for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for adenoviridae infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Immulina for virus diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inmazeb for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Isoniazid + RIFAPENTINE for latent tuberculosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ivermectin for asymptomatic infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivermectin for communicable diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivermectin for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Landiolol for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for cytomegalovirus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for epstein-barr virus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 0.01x IV Dose for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 0.1 x IV dose for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LBP-EC01 IV Infusion Dose for escherichia coli infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liposomal Amphotericin B (LAmB) for mycoses | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Dose FMT Capsule DE for clostridium infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 200 mg + PYRONARIDINE for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 200 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 330 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 500 mg + M5717 660 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 60 mg + PYRONARIDINE for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 60 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 660mg + PYRONARIDINE for asymptomatic infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 660mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine for tuberculosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Malaria Vaccine 257049 for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Malaria Vaccine 257049 + Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matrix-M with RH5.2 VLP and/or R21 for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MBK-01 for clostridium infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Meningococcal Group B Vaccine for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin for tuberculosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylenblue for malaria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| METRONIDAZOLE + Vancomycin + Loperamide + FECAL MICROBIOTA for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midodrine for sepsis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mosquirixs for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moxifloxacin + rifapentine for tuberculosis, lymph node | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-1018-H5 for influenza in birds | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mtbvac for tuberculosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N-Acetylcysteine (NAC) Treatment for tuberculosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nifurtimox for chagas disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Nirsevimab for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (3 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for haemophilus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for pneumococcal infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEDIACEL® and Prevenar® for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Penn Microbiome Therapy - 001 for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Penn Microbiome Therapy - 001 + Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pentacel®: DTaP-IPV/Hib combined for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pentacel®: DTaP-IPV/Hib combined for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Permethrin-treated lesu for malaria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Permethrin-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PG4 for pneumococcal infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for tuberculosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Posaconazole for chagas disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Povidone-iodine for surgical wound infection | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Primaquine for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Prone Position for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| prone positioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pvs230D1-EPA/Matrix-M for malaria, vivax | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pvs230D1-EPA/Matrix-M for parasitemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Quabodepistat for tuberculosis, multidrug-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21 in Matrix- M adjuvant vaccine for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21/Matrix-M - single vial formulation for malaria | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21/Matrix-M - two vial formulation for malaria | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rabies vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RBX2660 for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RBX2660 for communicable diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RBX2660 (microbiota suspension) for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for herpes zoster | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RSVPreF3 OA investigational vaccine for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S-337395 for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Single high dose of liposomal amphotericin B for histoplasmosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Soaked lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standardized kudzu for sexually transmitted diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sucrose for surgical wound infection | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tafenoquine for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Tafenoquine + chloroquine for malaria, vivax | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tafenoquine succinate for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for diphtheria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for tetanus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telacebec + Rifampicine for leprosy, multibacillary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telacebec 300 mg for leprosy, multibacillary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telacebec 600 mg for leprosy, multibacillary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) for gonorrhea | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml) for gonorrhea | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tetanus-Diphtheria booster for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Titrated weaning of vasopressin. for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Topical ceftazidime and vancomycin for surgical wound infection | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tradipitant for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for sepsis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 high-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 low-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valganciclovir for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vancomycin for clostridium infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vasopressin for shock, septic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Venous Excess Ultrasound (VEXUS)-Guided Management for shock, septic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vi-Typhoid Conjugate Vaccine (Vi-TCV) for typhoid fever | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viral Specific T-cells (VSTs) for virus diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VLA15 for lyme disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| VXA-G1.1-NN for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for coronavirus infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for chikungunya fever | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for dengue | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for zika virus infection | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zabdeno® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zelicapavir for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zoliflodacin for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |